Welcome to our dedicated page for Ocuphire Pharma SEC filings (Ticker: OCUP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OCUP issuer's SEC filings document Opus Genetics, Inc.'s public-company disclosures, including financial results, equity financing, governance changes, and material agreements tied to inherited retinal disease programs. Recent 8-K reports describe private placements of common stock, executive officer appointments and departures, and funding arrangements for gene therapy programs involving MERTK and RDH12.
The filings also include disclosure about manufacturing process development for OPGx-LCA5 and OPGx-BEST1, clinical-event reporting for Phentolamine Ophthalmic Solution 0.75%, exhibit filings, and related capital-structure and compensation matters. These records frame the issuer's biotechnology operations through formal event reports, ownership-sensitive agreements, and corporate governance disclosures.
Opus Genetics, Inc. Schedule 13G disclosures show that a group of affiliated Bios entities and related parties report shared beneficial ownership of 3,683,429 shares, representing 6.2% of the common stock (based on 59,661,197 shares outstanding as of May 12, 2025). The holdings are reported as shared voting and dispositive power; individual Bios Fund III vehicles report smaller direct stakes (for example, Bios Fund III QP, LP reports 2,801,953 shares or 4.7%). The filing identifies the security as Common Stock, par $0.0001, CUSIP 00887A204.
The Schedule includes standard confirmations of passive intent: the filers certify the securities were not acquired to change or influence issuer control. Contact and organizational details are provided for the issuer (principal office in Durham, NC) and the filers (principal office in Fort Worth, TX), and related organizational relationships among the Bios and Cavu entities are disclosed to explain shared power.
Opus Genetics (Nasdaq:OCUP) filed a Form 8-K disclosing topline results from VEGA-3, its second pivotal Phase 3 trial of Phentolamine Ophthalmic Solution 0.75 % for presbyopia. Numerical efficacy and safety data were not included, but management deemed the readout material and will host a webcast on June 26, 2025 at 8:00 a.m. ET to discuss the findings and give a corporate update.
The filing reiterates prior guidance that cash on hand should fund operations into 2H FY 2026, suggesting no immediate financing need. Exhibit 99.1 contains the full press release; no new contracts, financings, or governance changes were reported. Forward-looking-statement disclaimers reference previously disclosed risk factors.